5 days ago
1
mbbirdy/E+ via Getty Images
Ideaya Biosciences (NASDAQ:IDYA) got coverage initiation from Barclays and Citizens, reflecting increasing confidence in the company’s oncology pipeline.
Barclays launched with an Overweight rating and a $40 price target, while Citizens assigned a Market Outperform rating and a slightly higher $41 price target.
English (US) ·